Literature DB >> 33247770

β-Edorphin predict pregnancy outcome of PCOS and DOR women after IVF-ET.

Chan Zhang1, Shengxian Liu2, Gelin Liu2, Yuhui He2, Yanan Wang1, Fang Wang3.   

Abstract

PURPOSE: The present study aims to explore whether β-EP in serum (sβ-EP) and follicular fluid (ffβ-EP) could predict the in vitro fertilization (IVF) outcomes of patients with polycystic ovary syndrome (PCOS) and diminished ovarian reserve (DOR).
METHODS: 90 PCOS women, 50 DOR women, and 100 women with normal ovarian function (control group), who were all undergoing an IVF-embryo transfer trial, were included in the study. Biochemical characteristics, anti-Mullerian hormone (AMH), sβ-EP, ffβ-EP, embryo formation, and pregnancy indicators were assessed in all women. The correlations of AMH and β-EP with oocyte quality were analyzed. Population-based and age-category stratified receiver operating characteristic (ROC) curve analysis of AMH and β-EP for predicting pregnancy and live birth were performed.
RESULTS: Compared with the control group, the PCOS group had higher antral follicle count, testosterone, luteinizing hormone, AMH, sβ-EP, and ffβ-EP, which were lower in the DOR group. Meanwhile, the PCOS and DOR groups had higher cycle cancellation and miscarriage rates, and lower high quality embryo numbers. Correlation analysis showed that the oocyte quality were positively correlated with AMH, sβ-EP, and ffβ-EP. The population-based and age-stratified ROC curve analysis showed that sβ-EP and ffβ-EP had high sensitivity and specificity to predict pregnancy and live birth. Meanwhile, age-stratified AMH enhanced the sensitivity for prediction of live birth after IVF.
CONCLUSION: sβ-EP and ffβ-EP are different among women with PCOS, DOR, and normal ovarian function. β-EP can be used as a good predictor of clinical pregnancy and live birth after IVF.

Entities:  

Keywords:  Diminished ovarian reserve; IVF-ET; Live birth; Polycystic ovary syndrome; Pregnancy; β-EP

Mesh:

Substances:

Year:  2020        PMID: 33247770     DOI: 10.1007/s00404-020-05899-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  27 in total

1.  Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome.

Authors:  M Guido; V Pavone; M Ciampelli; F Murgia; A M Fulghesu; R Apa; A Caruso; S Mancuso; A Lanzone
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

2.  Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization.

Authors:  Cigdem Kunt; Gulnur Ozaksit; Raziye Keskin Kurt; Ayse Nur Cakir Gungor; Mine Kanat-Pektas; Sevtap Kilic; Arzu Dede
Journal:  Arch Gynecol Obstet       Date:  2011-03-29       Impact factor: 2.344

3.  Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease.

Authors:  S S Yen; P Vela; J Rankin
Journal:  J Clin Endocrinol Metab       Date:  1970-04       Impact factor: 5.958

4.  Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome.

Authors:  Franca Fruzzetti; Chiara Bersi; Donatella Parrini; Cabiria Ricci; Andrea Riccardo Genazzani
Journal:  Fertil Steril       Date:  2002-05       Impact factor: 7.329

Review 5.  Neuroendocrine aspects of polycystic ovary syndrome.

Authors:  J C Marshall; C A Eagleson
Journal:  Endocrinol Metab Clin North Am       Date:  1999-06       Impact factor: 4.741

Review 6.  Role of opioid antagonists in the treatment of women with glucoregulation abnormalities.

Authors:  M Guido; D Romualdi; A Lanzone
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

7.  Beta-endorphin and met-enkephalin in peritoneal and ovarian follicular fluids of fertile and postmenopausal women.

Authors:  F Petraglia; A Segre; F Facchinetti; D Campanini; M Ruspa; A R Genazzani
Journal:  Fertil Steril       Date:  1985-11       Impact factor: 7.329

8.  β-endorphins Plasma Level is Higher in Lean Polycystic Ovary Syndrome (PCOS) Women.

Authors:  M Kiałka; T Milewicz; M Spałkowska; M Krzyczkowska-Sendrakowska; B Wasyl; A Pełka; J Krzysiek
Journal:  Exp Clin Endocrinol Diabetes       Date:  2016-01-21       Impact factor: 2.949

9.  Prevalence of polycystic ovary syndrome in women in China: a large community-based study.

Authors:  Rong Li; Qiufang Zhang; Dongzi Yang; Shangwei Li; Shulan Lu; Xiaoke Wu; Zhaolian Wei; Xueru Song; Xiuxia Wang; Shuxin Fu; Jinfang Lin; Yimin Zhu; Yong Jiang; Huai L Feng; Jie Qiao
Journal:  Hum Reprod       Date:  2013-06-27       Impact factor: 6.918

10.  Beta endorphin in serum and follicular fluid of PCOS- and non-PCOS women.

Authors:  Nikolai Jaschke; Fabian Lunger; Ludwig Wildt; Beata Seeber
Journal:  Arch Gynecol Obstet       Date:  2018-05-28       Impact factor: 2.344

View more
  1 in total

Review 1.  From Pharmacology to Physiology: Endocrine Functions of μ-Opioid Receptor Networks.

Authors:  Nikolai Jaschke; Sophie Pählig; Ying-Xian Pan; Lorenz C Hofbauer; Andy Göbel; Tilman D Rachner
Journal:  Trends Endocrinol Metab       Date:  2021-03-03       Impact factor: 12.015

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.